Projet ORBITAL (Horizon 2020, appel à projets 2018)
Action : Doctoral Networks
Panel : Chemistry
Statut du projet : SIGNED

Diseases of the posterior segment of the eye are increasing considerably, partly due to an ageing population (almost 20% of the population of Europe now over 65). Despite accounting for approximately 55% of ocular conditions, only 5% of ocular product sales target the posterior segment due to the technical difficulties in developing safe, effective and easy-to-use formulations. Age-related Macular Degeneration and Diabetic retinopathy are some of the main cause of blindness and severe impairment of vision in patients. These diseases represent a considerable burden on patients and healthcare systems throughout the world. ORBITAL has the primary objective of recruiting excellent early stage researchers (ESRs) and developing the next generation of research leaders and drivers. There is a clear unmet clinical need for efficient, safe, non-invasive and patient-friendly strategies for the treatment of prevalent diseases of the posterior segment of the eye. With a necessary collaborative network of European and global experts, from academic, clinical and industrial sectors, ESRs will be exposed to an integrated and complementary network of expertise in materials science, nanotechnology, animal modeling, enhanced in-vitro testing, analytical chemistry and drug discovery. ORBITAL will build an intersectoral consortium with extensive experience in generating innovative technologies and training new researchers. ESRs will be exposed to a broad scientific landscape of complementary disciplines. With the combined skills and knowledge of the consortium, ESRs will be provided with the network, skills and knowledge to develop their careers while the extensive mobility of researchers will lead to increased knowledge transfer and collaborative research

Mots clés : drug delivery, ocular modeling, formulations, medical devices, posterior segment disease, in vivo models, ex vivo models, in vitro models, patient, oriented research, materials science

Participants :
- Ocupharm diagnostics sl (Espagne) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 250904.88 €
- University of Birmingham (Royaume-Uni) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 303172.56 €
- Hospital das forças armadas (hfar) - emgfa (Portugal) — Partner, organization partner, Organismes privés (hors enseignement), subvention : 0.0 €
- National University of Ireland (Irlande) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 274684.32 €
- University of Parma (Italie) — Partner, organization partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- Fighting Blindness (Irlande) — Partner, organization partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Loyola Medicine (Etats-Unis) — Partner, organization partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Universidad Complutense de Madrid (Espagne) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 250904.88 €
- The vision clinic (Irlande) — Partner, organization partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Hgbeyond materials sicence sl (Espagne) — Partner, organization partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Experimentica oy (Finlande) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 280805.76 €
- University of Lisbon (Portugal) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 237720.24 €
- South East Technological University (Irlande) — Coordinator, beneficiary, Enseignement supérieur ou secondaire, subvention : 824052.96 €
- Nanovector srl (Italie) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 261499.68 €
- Rowan University (Etats-Unis) — Partner, organization partner, Organismes privés (hors enseignement), subvention : 0.0 €
- University of Waterloo (Canada) — Partner, organization partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- Neuregenix limited (Royaume-Uni) — Partner, organization partner, Organismes privés (hors enseignement), subvention : 0.0 €
- University of Iceland (Islande) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 274331.16 €
- University of Santiago de Compostela (Espagne) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 501809.76 €
- State University System of Florida (Etats-Unis) — Partner, organization partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- Ocumedic inc. (Etats-Unis) — Partner, organization partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Queen's University Belfast (Royaume-Uni) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 606345.12 €